Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 106

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 106
---
 retain employees, exacerbating our equity compensation needs. In fact, the weighted average exercise price of all of our outstanding stock options is $40.73, with such stock options having a weighted average remaining term of 6.6 years. With the unprecedented competition for talent in the current marketplace, we need to be able to offer market-competitive equity awards to existing employees through annual equity grants and employee recognition, retention and promotion grants. We intend to utilize the Amended Plan as we have utilized the Current Plan: specifically, to grant equity awards to our employees, non-employeedirectors, consultants, and advisors in order to attract, incentivize, retain and reward those who are critical to our success. The compensation & people committee determined the requested number of shares for the Amended Plan based on our projections for new-hireequity awards, annual equity awards to our employees and non-employeedirectors, employee retention and promotion awards, as well as an assessment of the magnitude of the share reserve under the Amended Plan that our stockholders would likely find acceptable. If our stockholders approve the 2023 Plan Amendment, subject to adjustment in the event of stock splits and other similar events, awards may be made under the Amended Plan for up to a number of shares of common stock equal to the sum of: (i) 7,000,000 shares of common stock; and (ii) the number of shares of common stock subject to awards granted under our 2013 Stock Incentive Plan (the “2013 Plan”) that were outstanding as of June 13, 2023 (the date that the Current Plan was approved by our stockholders) and which awards expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (subject, however, in the case of incentive stock options, to any limitations under the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “Code”)). If our stockholders approve the 2023 Plan Amendment, subject to adjustment in the event of stock splits and other similar events, up to 7,000,000 of the shares of common stock available for issuance under the Amended Plan can be issued under incentive stock options. The Amended Plan does not include an evergreen provision and includes several features that are consistent with protecting the interests of our stockholders and sound corporate governance practices, as described below. In March 2025, we